Loading clinical trials...
Loading clinical trials...
STXBP1 and SYNGAP1 Related Disorders (RD) Natural History Study
The purpose of this study is to find out more about STXBP1 and SYNGAP1 related disorders. The information gathered by this study will be used to prepare for clinical treatment trials. The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care.
STXBP1 and SYNGAP1 related disorders are genetic disorders that cause differences in the synaptic transmission of the brain. Disease-causing variants in these genes lead to a spectrum of developmental delay that is most often severe, epileptic encephalopathies, and complex behavioral and psychiatric disorders. As there are multiple targeted therapies in development for these conditions, there is an urgent need to push forward a prospective natural history study in order to define specific disease outcomes in these genetic conditions. Participation may last up to five years and will involve up to 10 study visits. Detailed questions about health and medical history, physical exams, electrographic encephalogram (EEG) or quantitative EEG (qEEG) and some age-appropriate assessments of neurodevelopmental and behavioral function are some of the study procedures. Study procedures will occur during regularly scheduled clinic visits. Participants will undergo assessments at baseline visit and semi-annually (every 6 months for 2-5 years). The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care. The secondary objectives of the study are listed below: * To evaluate changes in neurodevelopmental and behavioral parameters as assessed by instruments appropriate to the study population. * To assess the burden of disease by quality-of-life instruments appropriate to the study population. * To assess the burden of performing multiple outcome measures and scales on the caregiver, participant, and clinical personnel. * To assess health care resource utilization
Age
All ages
Sex
ALL
Healthy Volunteers
No
Stanford Medicine Children's Health
Palo Alto, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Weill Cornell Medicine
New York, New York, United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Texas Children's Hospital
Houston, Texas, United States
Start Date
August 30, 2023
Primary Completion Date
August 30, 2028
Completion Date
December 30, 2028
Last Updated
October 29, 2025
600
ESTIMATED participants
Non-interventional study
OTHER
Lead Sponsor
Children's Hospital of Philadelphia
Collaborators
NCT07040774
NCT06235580
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions